Fluoxetine (Prozac) Dosing Guidelines
For adults with depression, start fluoxetine at 20 mg once daily in the morning; for OCD in adults, start at 20 mg daily with a therapeutic range of 20-60 mg/day (maximum 80 mg/day); for bulimia nervosa, use 60 mg/day; and for panic disorder, start at 10 mg/day for one week, then increase to 20 mg/day. 1
Adult Dosing by Indication
Major Depressive Disorder
- Initial dose: 20 mg once daily in the morning 1
- Dose adjustments: May increase after several weeks if insufficient response
- Typical therapeutic range: 20-80 mg/day
- Alternative: Prozac Weekly 90 mg capsule can be initiated 7 days after the last 20 mg daily dose for maintenance treatment 1
Obsessive-Compulsive Disorder (OCD)
- Initial dose: 20 mg once daily in the morning 1
- Therapeutic range: 20-60 mg/day (doses up to 80 mg/day have been well tolerated) 1
- Maximum dose: 80 mg/day 1
- Timing: Full therapeutic effect may be delayed until 5 weeks or longer 1
- Dose escalation: Consider increasing after several weeks if insufficient improvement; doses above 20 mg/day can be given once daily or divided (morning and noon) 1
Evidence note: Research shows the optimal dose for OCD efficacy is approximately 40 mg fluoxetine equivalent, with the dose-efficacy curve showing gradual increase up to 40 mg, then declining effectiveness at higher doses 2. Adult trials demonstrated all doses (20,40,60 mg) were superior to placebo, with a trend toward greater efficacy at 60 mg 3.
Bulimia Nervosa
- Recommended dose: 60 mg once daily in the morning 1
- Rationale: Only the 60 mg dose was statistically superior to placebo in reducing binge-eating and vomiting frequency 1
- Titration: May titrate up to target dose over several days for some patients 1
Panic Disorder
- Initial dose: 10 mg once daily 1
- After 1 week: Increase to 20 mg/day 1
- Most common dose in trials: 20 mg/day 1
- Dose escalation: May consider increasing after several weeks if no clinical improvement
- Maximum studied dose: 60 mg/day 1
Pediatric Dosing (Children and Adolescents)
OCD in Children and Adolescents
Adolescents and higher-weight children:
- Initial dose: 10 mg/day 1
- After 2 weeks: Increase to 20 mg/day 1
- Therapeutic range: 20-60 mg/day 1
- Additional increases: Consider after several more weeks if insufficient improvement 1
Lower-weight children:
- Initial dose: 10 mg/day 1
- Therapeutic range: 20-30 mg/day 1
- Important limitation: Experience with daily doses >20 mg is very minimal; no experience with doses >60 mg 1
Clinical evidence: Fluoxetine 20-60 mg/day was effective and well tolerated in pediatric OCD, though full effect may take more than 8 weeks to develop 4, 5, 6.
Depression in Children and Adolescents
- Evidence suggests that for partial responders to initial 10-20 mg/day treatment, dose escalation to 40-60 mg/day may benefit approximately two-thirds of patients 7
- However, approximately one-third of initial non-responders may respond to continued treatment at 20 mg/day with additional time 7
Special Populations
Elderly Patients
- Use lower or less frequent dosing 1
- Rationale: Age does not significantly affect fluoxetine pharmacokinetics, but elderly patients may have concurrent diseases or multiple medications 8
- The better tolerability profile compared to tricyclics makes fluoxetine particularly suitable for elderly patients 8
Hepatic Impairment
- Use lower or less frequent dosing 1
- Rationale: Fluoxetine has nonlinear pharmacokinetics and should be used with caution in patients with reduced metabolic capability 8
Renal Impairment
Patients with Concurrent Disease or Multiple Medications
- Consider lower or less frequent dosing 1
Dosing Principles and Monitoring
Titration Strategy
- For shorter half-life SSRIs (sertraline, citalopram): Increase at 1-2 week intervals 9
- For fluoxetine (longer half-life): Increase at approximately 3-4 week intervals 9
- Starting strategy: May start with subtherapeutic "test" dose since initial adverse effect can be anxiety or agitation 9
Monitoring Timeline
- Begin monitoring within 1-2 weeks of initiation 10
- Close monitoring for suicidal thoughts/behaviors is essential, especially in the first 1-2 months of treatment 10
- Monitor for agitation, irritability, or unusual behavioral changes 10
Response Assessment
- Modify treatment if inadequate response within 6-8 weeks 10
- Response rate to drug therapy may be as low as 50% 10
- For OCD, best-fitting model shows clinically significant improvement by week 6, maximal improvement by week 12 or later 9
Critical Safety Considerations
Drug Interactions
- Contraindicated with MAOIs: At least 14 days must elapse between discontinuing an MAOI and starting fluoxetine; at least 5 weeks (perhaps longer) must elapse after stopping fluoxetine before starting an MAOI 1
- CYP2D6 interactions: Fluoxetine may interact with drugs metabolized by CYP2D6 9
- Serotonin syndrome risk: Avoid concomitant use with other serotonergic drugs, MAOIs, St. John's wort, L-tryptophan, or illicit drugs (ecstasy, methamphetamine, cocaine, LSD) 9
Discontinuation
- Fluoxetine has lower discontinuation syndrome risk compared to shorter-acting SSRIs (paroxetine, fluvoxamine, sertraline) due to its long half-life (2-7 days for fluoxetine, 4-15 days for norfluoxetine) 8
- Gradual dose reduction is still recommended when discontinuing 1
Boxed Warning
- All SSRIs carry a boxed warning for suicidal thinking and behavior through age 24 years 9
- Pooled absolute rates: 1% for antidepressant-treated youth vs. 0.2% for placebo 9
- Number needed to harm: 143 (compared to number needed to treat of 3) 9
Treatment Selection Context
When choosing among second-generation antidepressants, select based on adverse effect profiles, cost, and patient preferences rather than efficacy differences, as no SSRI has demonstrated superior efficacy over another 10. However, fluoxetine has specific advantages including lower rates of sexual adverse events compared to paroxetine, and its long half-life provides a buffer for missed doses 10, 8.